Manages Credentials in Highly Regulated Pharmaceutical Industry
LOS GATOS, Calif., Oct. 22 /PRNewswire/ -- TriCipher today joined the SAFE(TM) (Signatures and Authentication for Everyone) BioPharma Association Vendor Partner Program, pledging to promote the adoption of the SAFE standards through the company's user and transaction authentication solutions. SAFE-approved credentials will seamlessly operate on TriCipher Armored Credential System (TACS), the company's strong authentication platform leveraging a variety of multi-factor credentials.
The industry group gives TriCipher access to forward-thinking corporate users of digital information processing, such as Amgen, AstraZeneca, Bristol-Myers Squibb, Genzyme, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, Procter & Gamble, Roche and Sanofi-Aventis. By agreeing to credentialing standards, these companies reduce the cost and time for pharmaceutical companies to advance drug development and deploy new business processes.
SAFE provides the industry's legal foundation for digital signatures and user authentication across pharmaceutical companies. Its standards are legally enforceable because they ensure user authentication, digital document integrity and auditable non-repudiation of users' actions.
"The pharmaceutical industry sets the bar for other industries with highly regulated and valuable online activities," said John De Santis, TriCipher's CEO. "SAFE and TriCipher make it possible to get more business value out of strong authentication credentials, increasing profits and better serving customers with faster product development and lower costs."
TriCipher, Inc. provides a unified authentication infrastructure to protect web and enterprise portals, the people that use them and the business process that flows through them against fraud and identity theft. The TriCipher Armored Credential System(TM) (TACS) is the first authentication system that enables companies to deploy and manage multiple types of credentials from a single infrastructure. Through this flexible "Authentication Ladder," TriCipher protects customer investment by adjusting authentication strength to defeat new threats and to meet regulatory changes without the need to implement a new infrastructure. Founded in 2000, TriCipher is headquartered in Los Gatos, Calif. The company is funded by ArrowPath Venture Capital, Intel Capital, RBC Technology Ventures, Trident Capital, and Wasatch Venture Fund. For more information, visit TriCipher on the web at http://www.tricipher.com
About SAFE-BioPharma Association
SAFE-BioPharma Association is the non-profit association that created and manages the SAFE(TM) digital identity and digital signature standard for the pharmaceutical and healthcare industries. Through the SAFE standard, the association promotes interoperability and integration among researchers, vendors, regulators, clinicians and other pharmaceutical and healthcare stakeholders. The SAFE standard provides a secure, enforceable, and regulatory compliant way to verify the identities of parties involved in business-to- business and business-to-regulator electronic transactions. SAFE stands for "Signatures and Authentication For Everyone." The Association's members include Amgen, AstraZeneca, Bristol-Myers Squibb, Genzyme, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, Procter & Gamble, Roche and Sanofi-Aventis. For more information visit http://www.safe-biopharma.org.
SAFE(TM) is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association.
|SOURCE TriCipher, Inc.|
Copyright©2007 PR Newswire.
All rights reserved